Ironwood Pharmaceuticals, Inc.· IRWD
🇺🇸 US · SmallBroad USNASDAQ
- Price
- $4.31
- Day
- -2.49%
- Mkt Cap
- $709.48M
- 52W Range
- $0.75 – $5.78
- Volume
- 5.73M
- Beta
- 0.21
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Despite the recent market selloff, earnings expectations continue to rise: The S&P 500's Q2 EPS is projected to grow by 37.9%, while net profit margins could reach a 15-year high. Buying the dip can present opportunities for investors. When fear fades, markets have historically returned to fundamentals. Using Seeking Alpha's Quant Tools, I found two Strong Buy stocks, beaten down in the past month, offering both solid growth and value.
Read full article
Ironwood Pharmaceuticals trades at a 40% discount to its risk-adjusted sum-of-the-parts valuation, anchored by LINZESS and apraglutide. I assign a 'Buy' rating on IRWD and a $6.3 price target, citing a margin of safety, but I also warn of a binary risk tied to apraglutide's pivotal trial. LINZESS faces a patent cliff in 2029, with revenue projected to decay rapidly following the entry of generic products.
Read full article
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read full article